GSC
LGND icon

Ground Swell Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Ground Swell Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-327
Closed -$13K – 2600
2014
Q2 		$13K Buy
+327
New +$13.3K 0.03% 603

Other funds holding LGND

RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ground Swell Capital's LGND Position: Q3 2014 in Review

Ground Swell Capital sold out of Ligand Pharmaceuticals (LGND) in Q3 2014, closing a stake of 327 shares — an estimated $13K sold.

Ground Swell Capital first reported a position in LGND in Q2 2014 and held it in 1 quarter. The position peaked at $13K in Q2 2014. 174 funds tracked by Wall St. Rank hold LGND as of Q3 2014.

  • Ground Swell Capital reported no remaining Ligand Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Ground Swell Capital sold 327 Ligand Pharmaceuticals shares in Q3 2014, an estimated $13K.
  • Ground Swell Capital first reported a position in Ligand Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Ground Swell Capital's Ligand Pharmaceuticals position peaked at $13K in Q2 2014.
  • 174 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.